Magnitude Biosciences Appoints New CEO Fozia Saleem to Drive Growth

4th October 2022, Durham, UK

Magnitude Biosciences Limited, a company located on the North East Technology Park (NETPark) in Sedgefield, and one of the world’s leading commercial providers of services for determining the effects of compounds on ageing, longevity, neurodegeneration, and reproductive health, today announces the appointment of Fozia Saleem as Chief Executive Officer (CEO).  David Weinkove, co-founder of Magnitude Biosciences who, as CEO and Chief Scientific Officer (CSO), has grown the business from an academic lab in Durham University in 2018 to a company with annual revenue of nearly £0.5m in 3 years, will continue as CSO.

Fozia joins from Broughton Life Sciences, a global life sciences consultancy, where she was Director of Product Development Services and a core member of the senior leadership team.  She has a PhD in molecular physiology from the University of Edinburgh and started her career in industry at GlaxoSmithKline. Fozia subsequently worked for British American Tobacco and Nicoventures Holdings where she had a wide range of responsibilities, including product development, project delivery and revenue growth.

With the North East fast becoming a hot bed of talent and innovation, the notable rise in Life Sciences and Biomedical companies in the region are proud to call it their home. An industry that has been supported not only through available funding but by key advocates including Labour’s Shadow Science MP Chi Onwurah, who has been lending her voice  as shadow science minister to the sector in Westminster and beyond. A voice that has most importantly helped in levelling up available investment and encouraging more of that funding back into the region. 

A word from the Magnitude Team:

"I am thrilled to welcome Fozia to the Company to lead the next stage of its growth. There is significant interest and investment in companies developing products to help us live longer and healthier lives. Magnitude Biosciences offers research services to enable companies to rapidly identify the most promising compounds and is poised to benefit from the growth in this area. David is internationally renowned for his expertise in C. elegans research and his leadership of the scientific team and ability to design experiments to meet the often-challenging needs of companies will continue to drive growth of the business."

- Sally Waterman, Chair, Magnitude Biosciences

"Really happy to welcome Fozia as our new CEO. She will further accelerate the amazing growth of our company, while I focus on our ground-breaking science to meet the research needs of our clients"

-David Weinkove, CSO, Magnitude Biosciences

"Looking forward to be joining the Magnitude Biosciences team, building on the foundations created by our 2 founders David Weinkove (CSO) and Chris Saunter (CTO), on generating high-quality, reproducible C. elegans data accelerating R&D across multiple industries."

-Fozia Saleem, CEO, Magnitude Biosciences

To find out how Magnitude Biosciences can support your research contact us via 

Press Contact:

Jessica Evans

Related Press Releases

Magnitude Biosciences: Revolutionising Research
Contract research organisation Magnitude Biosciences is projecting significant growth as it looks to...Read More
Life Sciences consortium celebrate collective multi-million Biomedical Catalyst 2023 Innovate UK grant
Press Release: 24th July 2023 Photo:  From left to right: Prof Carrie Ambler, (LightOx) Dr Sam Whit...Read More
Magnitude Biosciences awarded grant to accelerate the identification of compounds that could slow ageing or treat age-related diseases
Photo: The Magnitude Biosciences Team May 2023, Sedgefield, United Kingdom Magnitude Biosciences Lim...Read More
Magnitude Biosciences secures new investment to accelerate scaling of its specialist anti-ageing research services
Magnitude Biosciences Limited, a specialist provider of C. elegans research services to the longevit...Read More
Magnitude Biosciences Appoints New CEO Fozia Saleem to Drive Growth
North East UK Biotech Magnitude Biosciences announces new CEO, Fozia Saleem, to accelerate the growt...Read More
SMER28 Extends Healthspan – Revealing a New Target for Ageing Therapeutics
Biotech entrepreneur Ethan Perlstein works with Magnitude Biosciences to reveal a new target for age...Read More
Magnitude Biosciences CEO David Weinkove appointed new Chair of British Society for Research on Ageing
The British Society for the Research on Ageing (BSRA) announces its new Chair, biology of ageing res...Read More
Magnitude Biosciences, Perfectus Biomed Group and University of Kent Project Funded by National Biofilms Innovation Centre for Tackling and Exploiting Biofilms
The joint project for Magnitude Biosciences, Perfectus Biomed Group and the University of Kent aims ...Read More
Research on ageing leader Magnitude Biosciences expands its project delivery team to meet increased demand
Durham, UK - July 29, 2021 Magnitude Biosciences, the world’s leading commercial lab services prov...Read More
Magnitude Biosciences secures its second round of funding to support its pre-clinical research services
Magnitude Biosciences secures its second round of funding to support its pre-clinical research servi...Read More
Magnitude Biosciences announces new hires to support continued growth
Durham, UK - March 2021 Magnitude Biosciences, a spin-out from Durham University and the leading con...Read More
Magnitude Biosciences secures UK government Future Fund to expand its workforce.
Durham, UK - August 2020 Research into new medicines is needed more than ever, but research labs acr...Read More
Magnitude Biosciences' new COVID-19 compatible laboratory is fully operational and we are ready to support your research
Magnitude Biosciences moves its unique COVID-19 compatibletechnology to a new lab at NETPark in Sedg...Read More

Get regular updates in your inbox

Sign up to our newsletter today, to get access to the latest company and industry news